Lifeboat Foundation

Changes in epigenetic age acceleration (EAA) were significant over time, with the biggest increase — 4.9 years — seen immediately after the completion of radiotherapy (PChanges in epigenetic age acceleration (EAA) were significant over time, with the biggest increase — 4.9 years — seen immediately after the completion of radiotherapy (P0.001), reported Canhua Xiao, RN, PhD, of Emory University School of Nursing in Atlanta, and colleagues.

The study also demonstrated that EAA was associated with greater inflammation and fatigue, even up to a year after treatment, they noted in Cancer.

While chronological age is a strong risk factor for chronic health problems, Xiao and colleagues said that it often differs from epigenetic age and may be a limited predictor of age-associated disorders. On the other hand, they noted that epigenetic clocks, based on blood DNA methylation measures, have become reliable aging biomarkers.

If concerned, speak to your physician.

In patients with mild cognitive impairment, taking lipophilic statins more than doubles their risk of developing dementia compared to those who do not take statins. According to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting, positron emission tomography (PET) scans of lipophilic statin users revealed a highly significant decline in metabolism in the area of the brain that is first impacted by Alzheimer’s disease.

Statins are medications used to lower cholesterol and reduce the risk of heart attack or stroke. They are the most commonly used drugs in the developed world, and nearly 50 percent of Americans over age 75 use a statin. Different types of statins are available based on a patient’s health needs, including hydrophilic statins that focus on the liver and lipophilic statins that are distributed to tissues throughout the body.

Continue reading “Statins Used to Lower Cholesterol Linked to Doubled Risk of Developing Dementia” »

Researchers at McMaster University have developed a promising new cancer immunotherapy that uses cancer-killing cells genetically engineered outside the body to find and destroy malignant tumors.

The modified “natural killer” cells can differentiate between cancer cells and healthy cells that are often intermingled in and around tumors, destroying only the targeted cells.

The natural killer cells’ ability to distinguish the target cells, even from healthy cells that bear similar markers, brings new promise to this branch of immunotherapy, say members of the research team behind a paper published in the current issue of the journal iScience, newly posted on the PubMed database.

Washington — As the U.S. continues to navigate its way through the COVID-19 pandemic, Dr. Scott Gottlieb, the former commissioner of the Food and Drug Administration, said areas of the country could experience “very dense outbreaks” with the concerning Delta variant continuing to circulate.

“It’s going to be hyper-regionalized, where there are certain pockets of the country [where] we can have very dense outbreaks,” Gottlieb said Sunday on CBS News’ “Face the Nation.”

The most vulnerable areas continue to be those with low vaccination rates and low rates of immunity from prior infections. According to the Centers for Disease Control and Prevention, many southern states have vaccination rates that lag behind the national average.

Investigators at Cedars-Sinai and UC San Diego found that a synthetic compound given orally protected the liver against injury in an animal model for alcoholic hepatitis.

The study, co-authored by Dr. Ekihiro Seki, was published in the Proceedings of the Na… See More.

The most prevalent forms of ALD are fatty liver, alcoholic hepatitis and cirrhosis. Corticosteroids are the only treatment option for alcoholic hepatitis, or chronic inflammation of the liver, despite little evidence of long-term efficacy and considerable adverse side effects.

Continue reading “Compound Tested for Alcoholic Liver Disease” »

This research places the circadian clock as a central regulator of glucose production during lung cancer progression and provides important insight toward the development of novel therapeutics to target REV-ERBα to suppress cancer cell growth.

New research from the University of California, Irvine reveals how the circadian regulation of glucose production in the liver is lost during lung cancer progression, and how the resulting increase in glucose production may fuel cancer cell growth.

The new study titled, “Glucagon regulates the stability of REV-ERBα to modulate hepatic glucose production in a model of lung cancer-associated cachexia,” published today in Science Advances, illustrates how the circadian clock is regulated under conditions of stress such as during lung cancer progression and cancer-associated tissue wasting disease called cachexia.

Continue reading “Loss of circadian regulation allows for increase in glucose production during lung cancer” »

3 mins. This is really fascinating. Several applications, including quantum computing. Need special diamonds that scientists now can produce.

Diamonds are dazzling physicists with their powerful quantum properties. A particular impurity — the nitrogen-vacancy (NV) centre — allows diamonds to be used for everything from geolocation to diagnosing disease. This animation takes a closer look at these NV centres, and the carefully crafted artificial diamonds that make them possible.

AgomAb Therapeutics have announced the successful acquisition of a second round of funding ($74M) for research into the applications of antibodies for use in the field of regenerative medicine. Antibodies have already received a large amount of attention for their ability to positively effect numerous conditions such as inflammation, metabolic disorders, and non-healing wounds.

Antibodies are small protein molecules which are used by the body to ‘tag’ foreign pathogens in order for the immune system to identify and destroy them. What is unique about these antibodies is that due to their structure they will only attach themselves to a particular pathogen (at a particular site known as an antigen). In many cases, the binding of an antibody to a pathogen such as a virus is enough to completely inactive the pathogen, making it effectively harmless.

Where does all the blood for a young blood plasma transfusion come from? Young blood transfusions have been making waves in the media lately, with several different experiments providing exciting evidence that ‘young blood’ can rejuvenate the body and reverse the effects of ageing.